Sungkyunkwan University · Medicine
Professor Jong-Mu Sun's research lab specializes in translational oncology, with a primary focus on molecular biomarkers and personalized therapy in non-small cell lung cancer (NSCLC). The lab investigates the prognostic and predictive significance of genetic mutations such as KRAS and EGFR, aiming to improve treatment stratification and patient outcomes. Current research directions include identifying molecular subtypes of NSCLC, evaluating response to targeted therapies, and exploring the clinical implications of co-mutations. The lab integrates clinical data with molecular profiling to advance precision medicine in lung cancer.
Figures are computed from collected data and may differ slightly.
Clinical implications of KRAS mutations in advanced non-small cell lung cancer remain unclear. We retrospectively evaluated the prognostic and predictive value of KRAS mutations in patients with advanced NSCLC. Among 484 patients with available results for both KRAS and EGFR mutations, 39 (8%) had KRAS and 182 (38%) EGFR mutations, with two cases having both mutations. The median overall survivals for patients with KRAS mutations, EGFR mutations, or both wild types were 7.7, 38.0, and 15.0 month
Open papers in the app to read, cite, and organize with AI.
